Miriam R. Aure
Oslo, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer.
Journal: PloS one
Published: July 04, 2022
A regulatory network comprising let-7 miRNA and SMUG1 is associated with good prognosis in ER+ breast tumours.
Journal: Nucleic acids research
Published: June 17, 2022
Cis-regulatory mutations associate with transcriptional and post-transcriptional deregulation of gene regulatory programs in cancers.
Journal: Nucleic acids research
Published: May 18, 2022
NRF2 drives an oxidative stress response predictive of breast cancer.
Journal: Free radical biology & medicine
Published: January 27, 2022
Epigenetic alterations at distal enhancers are linked to proliferation in human breast cancer.
Journal: NAR cancer
Published: November 18, 2021
miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy.
Journal: Breast cancer (Dove Medical Press)
Published: September 08, 2021
Subtype and cell type specific expression of lncRNAs provide insight into breast cancer.
Journal: Communications biology
Published: August 12, 2021
MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro.
Journal: Scientific reports
Published: January 22, 2021
miRNA normalization enables joint analysis of several datasets to increase sensitivity and to reveal novel miRNAs differentially expressed in breast cancer.
Journal: PLoS computational biology
Published: June 10, 2020
DNA copy number motifs are strong and independent predictors of survival in breast cancer.
Journal: Communications biology
Published: October 11, 2019
Last Updated: 09/26/2026